Alto Neuroscience $ANRO
Shortfinder • Published December 30, 2025 • ML Model Identifies #1 Risk Stock
CORE INVESTMENT THESIS
ANRO faces acute supply risk as 8.4 million PIPE shares become freely tradeable with investors sitting on 200% unrealized gains.
Three converging factors create this setup: PIPE profit-taking pressure, toxic investor profiles with negative historical returns, and ANRO's own 22% decline following its last shelf effectiveness. Shortfinder's ML model assigns the highest risk score in their 800+ stock universe.
COMPANY OVERVIEW
KEY FINANCIAL METRICS
October 2025 private placement
As of report date
PIPE investors' current profit
At 100% volume capture
ML MODEL PREDICTIONS (v1.1.0)
Composite Risk Score: 0.0847 — Highest in 800+ stock universe
| Horizon | Decline Probability | Expected Magnitude |
|---|---|---|
| 1 Day | 51.8% | -3.2% |
| 5 Day | 54.2% | -6.8% |
| 20 Day | 48.7% | -9.1% |
HISTORICAL RETURNS AFTER DILUTION EVENTS
Shelf Effective
424B Prospectus
Shelf Effective
PIPE TRANSACTION STRUCTURE ($50M)
Total: 8,454,514 shares
Float Impact: 38% of pre-deal float
KEY PLAYERS — PIPE INVESTORS
TRADE STRUCTURE
Entry Zone
$17.00–$18.00
Price Target 1
$14.20 (−20%)
Price Target 2
$11.50 (−35%)
Stop-Loss
$21.00 (+18%)
Risk/Reward
1:1.5 to 1:2
Time Horizon
5–20 Days
Shortfinder's Verdict
According to Shortfinder, Alto Neuroscience ($ANRO) presents a high-conviction short opportunity. Their ML model identifies it as the highest-risk security in an 800+ stock universe. A $50 million PIPE with toxic investor participation became freely tradeable on December 10, 2025. PIPE investors hold $100 million in unrealized profit with every incentive to liquidate. Shortfinder concludes this is a "textbook" dilution setup with motive, means, and opportunity all aligned.
This dashboard summarizes Shortfinder's analysis. Nothing herein constitutes investment advice. Short selling involves unlimited loss potential.